February 8th 2025
Following promising results from a trial investigating the effects of 225Ac-SSO110 on Balb/c nude mice injected with the xenograft model of SCLC, IND clearance was granted by the FDA.
December 18th 2024
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non-Smal...
February 27, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Anlotinib Plus Irinotecan or Docetaxel Shows Promising Efficacy in SCLC
October 11th 2021Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.
Higher-Dose Radiotherapy Improved Survival, Maintained Level of Toxicity for Limited-Stage SCLC
March 29th 2021Data from The Lancet Oncology found that higher-dose radiotherapy of 60 Gy for patients with small cell lung cancer resulted in survival benefit while maintaining the toxicity profile compared with a radiotherapy at a dose of 45 Gy.
FDA Approves Trilaciclib for Patients With SCLC Being Treated With Chemo
February 12th 2021The approval of trilaciclib was based on results from a pooled analysis of intent-to-treat datasets from 3 studies of patients with extensive-stage small cell lung cancer in which patients received standard chemotherapy plus either trilaciclib or placebo.
Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to Chemo
January 30th 2021Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.
CASPIAN Update Supports Use of Durvalumab Plus Platinum-Etoposide in Frontline ES-SCLC
January 20th 2021The ongoing phase 3 CASPIAN trial evaluating the use of intravenous durvalumab, with or without tremelimumab, added to platinum–etoposide for the first-line treatment of extensive-stage small cell lung cancer demonstrated improved overall survival versus chemotherapy alone.
Bristol Myers Squibb Withdraws Nivolumab Indication for Treatment of SCLC
January 4th 2021Nivolumab was previously granted accelerated approval by the FDA for the treatment of patients with small cell lung cancer (SCLC) whose disease had progressed after platinum-based chemotherapy and at least 1 other line of therapy, but phase 3 trial results led to a decision to withdraw the indication.
Phase 3 ATLANTIS Study Fails to Meet Primary End Point of OS for Patients with SCLC
December 3rd 2020The study evaluated lurbinectedin (Zepzelca) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine for adult patients with small cell lung cancer whose disease progressed following 1 prior platinum-containing line of therapy.
Trilaciclib Reduces Need for Supportive Care Interventions from Chemo-Induced AEs in ES-SCLC
October 21st 2020Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.